SS-31

Clinical trials typically use dose escalation starting at 0.25 mg/kg daily for 3 days, increasing to 0.5 mg/kg daily for days 4-7, then 1.0 mg/kg daily for maintenance. For severe conditions, doses may be increased to 2.0 mg/kg daily based on tolerance and response. Administration is via subcutaneous injection once or twice daily, with consistent timing recommended for optimal results.

SS-31 dosing starts low and increases gradually. Most people begin with about 15-20mg daily (for someone weighing 70kg) for a few days, then double it for a week, then settle at about 70mg daily for ongoing treatment. For more serious conditions, the dose might go up to 140mg daily. It's given as a shot under the skin once or twice a day, like insulin but for cellular energy instead of blood sugar.

Subcutaneous injection is the primary route, typically in the abdomen, thigh, or upper arm with site rotation to prevent lipodystrophy. For hospitalized patients or severe conditions, intravenous infusion may be used. The peptide should be stored refrigerated and brought to room temperature before injection. Injection sites should be rotated systematically, and proper aseptic technique maintained to prevent infection.

Subcutaneous injection is the primary route, typically in the abdomen, thigh, or upper arm with site rotation to prevent lipodystrophy. For hospitalized patients or severe conditions, intravenous infusion may be used. The peptide should be stored refrigerated and brought to room temperature before injection. Injection sites should be rotated systematically, and proper aseptic technique maintained to prevent infection.

Injection Protocol

• •Subcutaneous injection per protocol
• •Rotate injection sites
• •Consistent daily timing
• •Follow protocol guidelines

Monitoring Schedule

• •Regular progress monitoring
• •Health parameter monitoring
• •Laboratory monitoring
• •Safety monitoring